What top creators are saying about Alumis Inc.(ALMS)
Clinical-stage biopharmaceutical company
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 1 scored insight about Alumis Inc..
Top creators covering Alumis Inc. (ALMS)
The 1 sources with the most insights about Alumis Inc. on Kazuha.
Latest insights about Alumis Inc. (ALMS)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Tuesday, September 1, 2026
Considered a potential rebound long play after an extreme sell-off caused by a failed lupus trial, supported by its secondary psoriasis pipeline.
Friday, March 20, 2026
Mentioned as a relevant company in the specialized biotech and rare disease space.
Tuesday, September 1, 2026
Considered a potential rebound long play after an extreme sell-off caused by a failed lupus trial, supported by its secondary psoriasis pipeline.
Friday, March 20, 2026
Mentioned as a relevant company in the specialized biotech and rare disease space.
Discussed alongside Alumis Inc. (ALMS)
Other assets that creators frequently mention in the same content as Alumis Inc..
Frequently asked
Which podcasters and creators cover Alumis Inc. (ALMS) the most?
The most active sources covering Alumis Inc. (ALMS) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Alumis Inc. (ALMS) are on Kazuha?
Kazuha has indexed 2 AI-extracted insights about Alumis Inc. (ALMS) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Alumis Inc. (ALMS)?
Creators covering Alumis Inc. (ALMS) most frequently also discuss SPRB, IONQ, FN, LITE, GPRO. See the "Discussed alongside" section above for full asset pages.